MOA Life Plus Co. Ltd. (KOSDAQ:142760)

South Korea flag South Korea · Delayed Price · Currency is KRW
1,747.00
-8.00 (-0.46%)
At close: Jan 26, 2026
62.81%
Market Cap67.15B
Revenue (ttm)9.80B -42.6%
Net Income-11.86B
EPS-339.68
Shares Out39.90M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume522,229
Average Volume650,500
Open1,751.00
Previous Close1,755.00
Day's Range1,727.00 - 1,760.00
52-Week Range999.00 - 2,250.00
Beta1.38
RSI45.68
Earnings DateMar 20, 2026

About MOA Life Plus

MOA Life Plus Co. Ltd. engages in the medicine and consumer business in South Korea. It offers P53, a target anti-cancer drug. The company’s pipeline products include BLS-H01, which is in phase 3 clinical trial for the treatment of cervical cancer; BLC-H03, a vaccine adjuvant that is in preclinical stage; BLS-M07 that has completed phase 2b clinical trial for the treatment of cervical cancer; and BLS-M22 that has completed phase 1 clinical trial for the treatment of Duchenne muscular dystrophy. It also provides health functional food and raw ma... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1999
Employees 42
Stock Exchange KOSDAQ
Ticker Symbol 142760
Full Company Profile

Financial Performance

Financial Statements